DEERFIELD, Ill. July 2, 2008
- Siemens Healthcare Diagnostics (www.siemens.com/diagnostics) received CE marking approval to sell the hepatitis B virus e-antigen (HBeAg) and antibody to the hepatitis B virus (anti-HBe) tests in the European marketplace. The two new tests may be used as an aid in the diagnosis of hepatitis B infections and to monitor the effectiveness of hepatitis B virus treatment. With these additions, the company now offers complete hepatitis A, B and C test panels that can be run on the high-throughput ADVIA Centaur® and ADVIA Centaur XP immunoassay systems. Consolidating all A, B and C hepatitis tests onto one instrument creates cost efficiencies by reducing the time needed for laboratory personnel to produce test results.
In addition, Siemens Healthcare received CE marking approval to sell multiple hepatitis B tests for use on the ADVIA Centaur CP immunoassay system in the European marketplace. This allows mid-sized clinical laboratories to consolidate hepatitis B tests with other immunoassay tests onto one compact, bench top, fully automated immunoassay system. This, again, creates cost efficiencies by reducing the time needed for laboratory personnel to produce test results. The hepatitis B tests approved for use on the ADVIA Centaur CP system are hepatitis B surface antigen (HBsAg), HBsAg confirmation, total antibody to the core antigen of the hepatitis B virus (HBcTotal) and IgM to the core antigen of the hepatitis B virus (HBcIgM). All of these tests are routinely requested by physicians to screen and diagnose hepatitis B infections in patients.
“These introductions demonstrate Siemens’ commitment to making quality hepatitis tests available to all sizes of laboratories,” said Jay Snyder, vice president, global clinical chemistry, immunoassay and automation, Siemens Healthcare Diagnostics. “They also illustrate Siemens’ success to migrate infectious disease tests from one ADVIA Centaur immunoassay platform to another, allowing customers to benefit from standardized test results. In addition, consolidating tests onto a single instrument addresses one of the laboratory’s biggest challenges to improve operational efficiency.”
The ADVIA Centaur immunoassay systems are used to screen, diagnose and monitor a wide variety of disease states routinely tested for in the laboratory. Hepatitis testing is now offered on all of the company’s ADVIA Centaur immunoassay systems. All new hepatitis B tests available on the ADVIA Centaur immunoassay systems are also under development for use in the United States.
The Siemens Healthcare Sector
is one of the world’s largest suppliers to the healthcare industry. The company is a renowned medical solutions provider with core competence and innovative strength in diagnostic and therapeutic technologies as well as in knowledge engineering, including information technology and system integration. With its laboratory diagnostics acquisitions, Siemens Healthcare is the first integrated healthcare company, bringing together imaging and lab diagnostics, therapy, and healthcare information technology solutions, supplemented by consulting and support services. Siemens Healthcare delivers solutions across the entire continuum of care – from prevention and early detection, to diagnosis, therapy and care. Additionally, Siemens Healthcare is the global market leader in innovative hearing instruments. The company employs more than 49,000 people worldwide and operates in 130 countries. In the fiscal year 2007 (Sept. 30), Siemens Healthcare reported sales of €9.85 billion, orders of €10.27 billion, and group profit of €1.32 billion. Further information can be found by visiting www.siemens.com/healthcare